This paper is based on interviews conducted prior to the COVID19 pandemic and therefore it is not a discussion topic covered in the document. However, COVID19 has underlined the importance of diversifying the vaccine supply base and manufacturing capacity in developing regions. As policy makers, entrepreneurs, investors and others develop and implement approaches to achieving these ends, it will be imperative that the complexities of the undertaking are considered and that lessons learned during the evolution of the vaccine sector are built upon. Hence, the insights from experts in the field of vaccine manufacturing captured in this document are even more prescient in light of the global pandemic.